Objectives. Atomoxetine seems to be as effective for treating attention-deficit/hyperactivity disorder (ADHD) when the daily dose is administered once in morning divided and evening. In present study, efficacy of atomoxetine among children with ADHD was assessed throughout day, including evening early morning. Another goal determine how treatment it possible discern a specific effect drug on symptoms. Methods. This study randomized, multicenter, double-blind, placebo-controlled trial...

This study compared the effects of atomoxetine and methylphenidate on sleep children with attention-deficit/hyperactivity disorder (ADHD). also efficacy these medications for treating ADHD in children. Randomized, double-blind, crossover trial. Two disorders centers United States; 1 a private-practice setting hospital setting. 85 diagnosed ADHD. Twice-daily thrice-daily methylphenidate, each approximately 7 weeks. Relative to baseline, actigraphy data indicated that increased sleep-onset...

To evaluate the effect of atomoxetine (ATX) on attention-deficit/hyperactivity disorder (ADHD) and comorbid social anxiety in adults.Randomized, double-blind, placebo-controlled, conducted adults with ADHD disorder. Patients received 40-100 mg ATX (n=224) or placebo (n=218) for 14 weeks following a 2-week lead-in period. Efficacy measures included Conners' Adult Rating Scale: Investigator-Rated: Screening Version (CAARS:Inv:SV), Liebowitz Social Anxiety Scale (LSAS), Clinical Global...

This randomized, double-blind, placebo-controlled, 6-month trial examined the efficacy and safety of once-daily morning-dosed atomoxetine in adult patients with attention-deficit/hyperactivity disorder (ADHD) ameliorating symptoms through evening hours. Patients received (n = 250) or placebo 251) morning for approximately 6 months. The measures included Adult ADHD Investigator Symptom Rating Scale (AISRS), Conners' Scale-Investigator Rated: Screening Version, Clinical Global...

Validation of the Adult ADHD Investigator Symptom Rating Scale (AISRS) that measures aspects in adults.Psychometric properties AISRS total and subscales are analyzed compared to Conners' Attention-Deficit/Hyperactivity Disorder Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Clinical Global Impression-ADHD-Severity using data from a placebo-controlled 6-month clinical trial once-daily atomoxetine.The has high internal consistency, good convergent, discriminant validities; modest...

Most conventional, oral, preventive treatments for migraine are non-specific and ~50% of patients discontinue them within six months. In 2018, the Food Drug Administration approved three treatments: monoclonal antibodies (mAb) targeting calcitonin gene-related peptide (CGRP) pathway implicated in migraine; galcanezumab fremanezumab which target CGRP ligand; erenumab targets receptor. Real-world treatment patterns mAb limited.To compare real-world mAb, specifically versus standard-of-care...

Objective. The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a potent inhibitor the presynaptic norepinephrine transporter minimal affinity for other noradrenergic receptors or neurotransmitter transporters receptors. Methods. A total 291 children who were 7 to 13 years age and met Diagnostic Statistical Manual Mental Disorders, Fourth Edition criteria ADHD participated 1 2 combined, double-blind,...

To assess change in hospitalization and cost of care from 6 months pre- to post-initiation on any depot antipsychotic among schizophrenia patients.Using a large United States commercial claims encounters database, patients younger than 65 years diagnosed with were identified. Patients initiated studied mirror-image design rates, mean duration hospitalized, cost. McNemar's test paired t-tests compared the proportions hospitalized duration. Paired t-test bootstrapping methods costs.In these (n...

The effects of cocaine use and withdrawal on mood sleep were examined. Three cocaine-dependent men lived in an inpatient facility for approximately 4 weeks, which included initial abstinence phase (8-10 days), a administration (5 2nd (14-16 days). During the phase, was administered intranasally few hours before bedtime. day, daytime sleepiness measured, monitored each night. Cocaine produced typical changes blood pressure, severely disrupted. Following Phase 2, there no that indicative...

Introduction: Nocturnal enuresis is a condition in which children at least 5 years of age are incontinent urine night. Atomoxetine, potent inhibitor the presynaptic norepinephrine transporter, used to treat attention-deficit/hyperactivity disorder (ADHD). This study tested hypothesis that atomoxetine will provide significant therapeutic benefit for nocturnal patients with diagnosis enuresis. Methods: Atomoxetine's efficacy improving was studied 87 pediatric subjects using an outpatient,...

To assess the effect of atomoxetine on ADHD-related executive functions over a 6-month period using Brown Attention-Deficit Disorder Scale (BADDS) for Adults, normed, 40-item, self-report scale in randomized, double-blind, placebo-controlled clinical trial.In double-blind trial, adults with ADHD received either 25 to 100 mg/day or placebo 6 months. Patients completed BADDS report their current daily functioning 5 clusters impairments functioning: (1) Organizing and Activating Work; (2)...

To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment schizophrenia from patients' their clinicians' perspectives.Two measures were previously developed to assess Reasons Antipsychotic Discontinuation/Continuation (RAD), one patient's perspective another clinician's perspective. These administered acutely ill patients enrolled a 12-week study (N = 596) clinicians. The RAD was assessed at baseline endpoint. rated on 5-point scale 'primary...

In this 3-arm, randomized, double-blind trial, once-daily morning-dosed atomoxetine, evening-dosed and placebo were compared for treating pediatric attention-deficit/hyperactivity disorder (ADHD). Patients received morning atomoxetine/evening (n = 102), placebo/evening atomoxetine 93), or 93) about 6 weeks. Core symptom efficacy was measured at weeks 0, 1, 3, 6. Parent assessments of the child’s home behaviors in evening early collected daily during first 2 treatment. Morning-dosed...